Literature DB >> 14595565

Transscleral resection of a ciliary body leiomyoma in a child: case report and review of the literature.

Miriam N Richter1, Nikolaos E Bechrakis, G Stoltenburg-Didinger, Michael H Foerster.   

Abstract

PURPOSE: To present the case of a patient with leiomyoma of the ciliary body and discuss the histological features and treatment of this rare intraocular tumor. METHODS/CASE REPORT: A 13-year-old boy presented with an asymptomatic tumor of the right eye. Visual acuity was 20/20 in both eyes. Ophthalmoscopy revealed an amelanotic, vascularized ciliary body tumor with exudative retinal detachment and partial transillumination. On ultrasound examination the tumor height was 8 mm and a low internal reflectivity was found. T2-weighted MRI scans showed a hypointense and T1-weighted scans a hyperintense intraocular mass with significant Gd-TPA enhancement. On the assumption that the diagnosis was consistent with an amelanotic ciliary body melanoma, a transscleral resection with adjuvant ruthenium-106 brachytherapy was performed. Visual acuity was 20/40 at 6 months after the operation.
RESULTS: Routine stains revealed a pleomorphic tumor composed mainly of spindle cells with palisading in some areas and a prominent intercellular fibrillary background. Immunohistochemistry showed positivity for desmin, vimentin and actin. No reactivity with S-100 and HMB-45 was seen. Intracytoplasmatic filaments and micropinocytotic vesicles were detected by transmission electron microscopy. These findings were consistent with the diagnosis of a ciliary body leiomyoma.
CONCLUSION: Typical clinical features of leiomyoma include a dome-shaped configuration and translucency, but the final diagnosis can only be confirmed by histology with the aid of immunohistochemistry and electron microscopy. Though rare, leiomyoma should be considered in the differential diagnosis of amelanotic uveal tumors. Transscleral resection is the treatment of choice of anterior uveal leiomyomas, with a fairly good visual prognosis.

Entities:  

Mesh:

Year:  2003        PMID: 14595565     DOI: 10.1007/s00417-003-0766-x

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  32 in total

1.  Mitochondria-rich epithelioid leiomyoma of the ciliary body.

Authors:  Ursula Schlötzer-Schrehardt; Anselm Jünemann; Gottfried O H Naumann
Journal:  Arch Ophthalmol       Date:  2002-01

2.  Leiomyoma of the ciliary body. Report of 2 cases.

Authors:  S Heegaard; P K Jensen; E Scherfig; J U Prause
Journal:  Acta Ophthalmol Scand       Date:  1999-12

Review 3.  Immunohistochemistry in the differential diagnosis of soft tissue tumors.

Authors:  J S Brooks
Journal:  Monogr Pathol       Date:  1996

4.  Biopsy in indeterminate intraocular tumors.

Authors:  Nikolaos E Bechrakis; Michael H Foerster; Norbert Bornfeld
Journal:  Ophthalmology       Date:  2002-02       Impact factor: 12.079

5.  Mesectodermal leiomyoma of the ciliary body extending into the anterior chamber.

Authors:  J G Orsoni; B Daicker; F Cardillo Piccolino
Journal:  Ophthalmologica       Date:  1985       Impact factor: 3.250

6.  Ultrastructural spectrum of hemangiopericytoma: a comparative study of fetal, adult, and neoplastic pericytes.

Authors:  I Dardick; S P Hammar; B W Scheithauer
Journal:  Ultrastruct Pathol       Date:  1989 Mar-Jun       Impact factor: 1.094

7.  Transscleral leiomyoma.

Authors:  C L Shields; J A Shields; M P Varenhorst
Journal:  Ophthalmology       Date:  1991-01       Impact factor: 12.079

8.  Mesectodermal leiomyoma of the ciliary body associated with a nevus.

Authors:  F A Jakobiec; T Iwamoto
Journal:  Arch Ophthalmol       Date:  1978-04

Review 9.  Observations on seven cases of intraocular leiomyoma. The 1993 Byron Demorest Lecture.

Authors:  J A Shields; C L Shields; R C Eagle; P De Potter
Journal:  Arch Ophthalmol       Date:  1994-04

Review 10.  Clinical and pathological status of mesectodermal leiomyoma of the ciliary body. A case report and review of the literature.

Authors:  H Ishigooka; H Yamabe; Y Kobashi; M Nagata
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.